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Abstract: Environmental fate assessment of chiral pharmaceuticals is an important issue 
and little information is known about enantioselectivity in the environment. This kind of 
information is important for regulamentation of pharmaceutical industry and chiral 
switching 
processes. Fluoxetine (FLX), an anti-depressant worldwide used, is a chiral 
pharmaceutical prescribed in racemic form, and its main metabolite norfluoxetine (NFLX) 
is also chiral. In this study, enantioselective degradation of rac-FLX and degradation of its 
enantiomers separately, in a minimal salts medium inoculated by a bacterium consortium 
was examined both at light and dark conditions. The assays were performed in a shaker 
at aerobic and ambient temperature conditions. The analytical method used was an 
enantioselective HPLC-FD method using a vancomycin-based chiral stationary phase in 
reversed mode to monitor enantiomers of FLX and NFLX. No degradation of enantiomers 
of FLX in the abiotic controls was observed. In the all assays (R)-FLX was degraded faster 
and totally until day 24th while (S)-FLX remained up to 20% of its initial concentration 
until the end of the experiment (38 days). NFLX was detected in all biotic experiments. 
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